Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label CA125. Show all posts
Showing posts with label CA125. Show all posts
Sunday, May 27, 2012

Does HE4 have a role in the recurrence of ovarian cancer? | 2012 ASCO Annual Meeting Abstracts (+ links to related ovarian abstracts)

›
Does HE4 have a role in the recurrence of ovarian cancer? | 2012 ASCO Annual Meeting Abstracts Abstract: Background: Human epididymis pr...
Friday, May 18, 2012

paywalled: CT diagnosis of intrasplenic metastasis from ovarian carcinoma

›
CT diagnosis of intrasplenic metastasis from ovarian carcinoma  We concluded that CT can demonstrate intraparenchymal and infiltrative sp...
Thursday, May 17, 2012

paywalled: Two-marker Combinations for Preoperative Discrimination of Benign and Malignant Ovarian Masses

›
Two-marker Combinations for Preoperative Discrimination of Benign and Malignant Ovarian Masses Abstract Background:  When caring fo...
Tuesday, May 01, 2012

paywalled: Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon

›
Mucin 16 (cancer antigen 125) expression in human... [Hum Pathol. 2012] - PubMed - NCBI Hum Pathol. 2012 Apr 26 Mucin 16 ( cancer a...
Thursday, April 26, 2012

paywalled: Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.

›
Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer . Abstract The aim of this study was to investigate the role of biomark...
Monday, April 09, 2012

Abstract - Biotargets of Cancer in Current Clinical Practice - Ovarian Cancer

›
  Medicine Biotargets of Cancer in Current Clinical Practice Current Clinical Pathology , ...

abstract: Adnexal masses in women with breast cancer

›
Adnexal masses in women with breast cancer : Background Adnexal masses detected in breast cancer survivors are of particular concern b...

Blogger's Opinion: repost (2011) : Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial - Moore - 2011 - Cancer - Wiley Online Library

›
Blogger's Note/Opinion:   efforts to improve on the existing CA125 biomarkers remain elusive, as we speak;  this may be confirmed by th...
1 comment:
Friday, April 06, 2012

abstract: Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy

›
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treate...
Friday, March 30, 2012

abstract: Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders

›
Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders : Publication year: 2012 Objective Th...
Thursday, March 22, 2012

March 22, 2012: Journal of Ovarian Research | open access | The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: A retrospective study

›
Blogger's Note: past studies also confirm the connection between doubling of CA125/nadir, focus on remote care/followup Journal of Ov...
Wednesday, March 21, 2012

(open access journal) Journal of Ovarian Research - Struma Ovarii associated with Pseudo-Meig's syndrome and high serum level of CA 125; a case report (Iran)

›
Journal of Ovarian Research -  Struma Ovarii associated with Pseudo-Meig's syndrome and high serum level of CA 125; a case report Case...

abstract: HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma.

›
HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma Abstract ...
Tuesday, March 20, 2012

REPOST: CA-125: To Monitor or Not to Monitor?: Evidence Against Monitoring CA-125

›
 Blogger's Note: Medscape requires registration (free) CA-125: To Monitor or Not to Monitor?: Evidence Against Monitoring CA-125   F...

Controversies Continue in NCCN Ovarian Cancer Guidelines

›
Controversies Continue in NCCN Ovarian Cancer Guidelines Medscape Medical News from the:   National Comprehensive Cancer Network (NCC...

The Chinese-German Journal of Clinical Oncology - abstract: Clinical significance of CA125 regression in chemotherapy of advanced ovarian cancer

›
The Chinese-German Journal of Clinical Oncology Abstract Objective   The aim of this study was to compare the serum CA125 regres...
Monday, March 12, 2012

open access: Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women (comparison to CA-125)

›
Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer Performance of a multianalyte test as an aid for the diag...
Sunday, March 11, 2012

abstract: Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125 (includes graphic/study of 23 patients)

›
 Highlights (in study of 23 patients) ► Three new markers were compared to CA125 for lead time to ovarian cancer recurrence. ► HE4 elevat...
Friday, March 09, 2012

open access: CA-125: To Monitor or Not to Monitor?: Evidence Against Monitoring CA-125 For Ovarian Cancer Patients in Remission (Dr's Rustin, Karlan, Markman)

›
CA-125: To Monitor or Not to Monitor?: Evidence Against Monitoring CA-125  For Ovarian Cancer Patients in Remission Gordon Rustin, MD;...
Wednesday, February 29, 2012

Advanced Ovarian Cancer -- A Clinical Context Report - in Clinical Context, Ovarian Cancer from MedPage Today (overview: surgery, treatments, CA125...)

›